<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05074862</url>
  </required_header>
  <id_info>
    <org_study_id>KETO-ICU 1-10-72-231-21</org_study_id>
    <nct_id>NCT05074862</nct_id>
  </id_info>
  <brief_title>Effects of Ketosis on Muscle Kinetics and Signaling During Critical Illness.</brief_title>
  <acronym>KETO-ICU</acronym>
  <official_title>Effects of Ketosis on Muscle Kinetics and Signaling During Critical Illness.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Patients with critical illness in the intensive care unit (ICU) experience marked skeletal&#xD;
      muscle weakness, muscle atrophy and disability in physical function, commonly termed&#xD;
      ICU-acquired weakness (ICU-AW). The pathophysiology of ICU-AW is complex, but a key feature&#xD;
      of skeletal muscle wasting is disturbed protein metabolism reflected in both increased rate&#xD;
      of muscle protein degradation and reduced synthesis. Treatment with 3-OHB seems a promising&#xD;
      new anticatabolic treatment in patients with critical illness, preventing ICU-AW. To date, no&#xD;
      data exist on the clinical and functional effects of ketone body modulation in patients with&#xD;
      critical illness.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      The aim to investigate the effect of exogenous 3-OHB administration on muscle protein&#xD;
      kinetics and lipolysis in patients with critical illness, aiming towards preventing ICU-AW.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      A randomized double-blind isocaloric placebo-controlled cross-over study in 10 mechanically&#xD;
      ventilated patients with critical illness in the ICU.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Evaluation of whole-body and focal leg protein kinetics using labeled phenylalanine and&#xD;
      tyrosine tracers. Assessment of free fatty acid (FFA) turnover using a labeled palmitate&#xD;
      tracer. Femoral arterial blood flow (assessed with pulsed-wave Doppler ultrasound) is&#xD;
      evaluated once per study period. Blood- and urinary samples are collected routinely&#xD;
      throughout the study day. Whenever feasible, muscle and fat biopsies will be taken for&#xD;
      analysis of protein and adipocyte metabolic signaling and mitochondrial function.&#xD;
&#xD;
      Perspectives: This investigation may grant essential knowledge on ketosis in critical&#xD;
      illness. This may lead to larger clinical trials, and hopefully a new and better treatment&#xD;
      strategy aimed at preserving muscle mass and function during and improving recovery after&#xD;
      critical illness.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A randomized double-blind isocaloric placebo-controlled cross-over study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Net leg phenylalanine release</measure>
    <time_frame>3 hours</time_frame>
    <description>As measured by rate of phenylalanine appearance in relation with the rate of disappearance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in rate of appearance of phenylalanine over the leg.</measure>
    <time_frame>3 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in rate of disappearance of phenylalanine over the leg.</measure>
    <time_frame>3 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole body palmitate flux</measure>
    <time_frame>3 hours.</time_frame>
    <description>As measured by rate of appearance of a palmitate-tracer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in arterial pH.</measure>
    <time_frame>3 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory cytokines (IL-1, IL-6, IL-18, TNFa)</measure>
    <time_frame>3 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in intramyocellular protein metabolic signalling pathways.</measure>
    <time_frame>3 hours.</time_frame>
    <description>The Akt-, mTor-, and ubiquitin-proteasome pathways.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Intensive Care Unit Acquired Weakness</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Ketone monoester (3-OHB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weight-adjusted dose of 3-OHB Monoester (KetoneAID KE4, Virginia, US). Bolus of 200 mg/kg followed by a 2-hour continuous enteral infusion with a dosing of 150 mg/kg/hour (maximal total dose 50 grams). There is a 1-hour lag between the bolus and the continuous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin- and fatbased placebo in isocaloric, isovolemic dose to the experimental arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>KetoneAid KE4 Pro Monoester</intervention_name>
    <description>A dietary supplement containing ketone monoester.</description>
    <arm_group_label>Ketone monoester (3-OHB)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin and fat-based placebo</intervention_name>
    <description>Dosis isocaloric to the KetoneAid Arm</description>
    <arm_group_label>Placebo Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Invasive mechanical ventilation via a cuffed endotracheal or tracheotomy tube&#xD;
             initiated &lt;48 hours of ICU admission.&#xD;
&#xD;
          -  Expected ICU stay on ventilator support for ≥3 days.&#xD;
&#xD;
          -  Expected survival of ICU admission.&#xD;
&#xD;
          -  Adults (≥18 years).&#xD;
&#xD;
          -  Multi-organ failure (Sequential Organ Failure Assessment Score [SOFA] score &gt;2 in 2 or&#xD;
             more domains).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Moribund or expected withholding treatment within 48 hours as judged by the&#xD;
             investigator.&#xD;
&#xD;
          -  Palliative goals of care.&#xD;
&#xD;
          -  Contraindication for enteral nutrition.&#xD;
&#xD;
          -  Suspected other cause of paresis/paralysis (i.e. stroke or primary neuromuscular&#xD;
             disorders).&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Known severe musculoskeletal or neurological disability.&#xD;
&#xD;
          -  Diabetic ketoacidosis.&#xD;
&#xD;
          -  Disseminated cancer.&#xD;
&#xD;
          -  Phenylketonuria.&#xD;
&#xD;
          -  BMI ≤17 or deemed malnourished as judged by the investigator.&#xD;
&#xD;
          -  BMI &gt;40.&#xD;
&#xD;
          -  Other conditions making the patient unsuitable for the study (as judged by the&#xD;
             investigator).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kristoffer Berg-Hansen, MD</last_name>
    <phone>60540700</phone>
    <email>krbhan@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Niels Møller, Prof.</last_name>
    <email>niels.moeller@clin.au.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Kristoffer Berg-Hansen, MD</last_name>
      <email>krisbe@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Niels Møller, Prof.</last_name>
      <email>niels.moeller@clin.au.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 17, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Kristoffer Berg-Hansen</investigator_full_name>
    <investigator_title>MD, Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

